Key Facts

Invested since 2015
Based in Bavaria

About the company

Thermosome is a clinical-stage drug development company focused on targeted tumor therapy combined with immune stimulation for improved cancer therapy. At its core is a novel, proprietary tumor targeting approach that allows for significantly increased local drug concentrations and improved tumor penetration to achieve improved clinical treatment efficacy. The lead candidate THE001 is a thermosensitive formulation of doxorubicin being developed in soft tissue sarcoma.

Do you want to

know more about this company?

Zum Artikel

Dr. Caroline Fichtner Principal

Dr. Caroline FichtnerPrincipal

Thermosome in the news

Zum Artikel

News

6. April 2016

Thermosome raises €4.6m with first financing round and a research grant from the German government

More startups from Life Sciences